Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III

Pallavi Madhiraju- November 5, 2023 0

Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination ... Read More

China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment

Pallavi Madhiraju- August 20, 2023 0

China's National Medical Products Administration (NMPA) has approved AstraZeneca's Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic ... Read More

AstraZeneca Pharma India gets Dapagliflozin 10mg import and market permission from CDSCO

Pallavi Madhiraju- November 27, 2022 0

AstraZeneca Pharma India has secured an import and market permission for Dapagliflozin (Forxiga) tablets of 10 mg from India’s Central Drugs Standard Control Organisation (CDSCO), ... Read More

Glenmark Pharmaceuticals launches Type 2 diabetes drug Zita D in India

Pallavi Madhiraju- October 20, 2022 0

Glenmark Pharmaceuticals has launched Zita D the brand name for Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination in India for the treatment of Type ... Read More

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

pallavi123- May 30, 2021 0

AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in ... Read More

AstraZeneca’s Forxiga wins approval in China for heart failure treatment

pharmanewsdaily- February 7, 2021 0

AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More

AstraZeneca gets FDA breakthrough status for Farxiga in CKD

pharmanewsdaily- October 4, 2020 0

AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with ... Read More

Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI

pharmanewsdaily- July 20, 2020 0

AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) ... Read More